Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

首钢朗泽
Shougang LanzaTech

BEIJING SHOUGANG LANZATECH TECHNOLOGY CO., LTD.
北京首鋼朗澤科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2553)

VOLUNTARY ANNOUNCEMENT
PROPOSED GRANT OF GENERAL MANDATE TO REPURCHASE H SHARES

This announcement is made by Beijing Shougang LanzaTech Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors (the "**Board**") of the Company hereby announces that it held a meeting on November 9, 2026 and resolved to propose to the shareholders of the Company at the extraordinary general meeting of the Company (the "**EGM**") to grant a general mandate to the Board (the "**Repurchase Mandate**") to repurchase certain H shares of the Company in accordance with the relevant domestic and overseas laws and regulations, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Codes on Takeovers and Mergers and Share Buy-backs (the "**Takeovers Code**").

The funds for the repurchase will be financed by the Company's own funds. Pursuant to the H Share Repurchase Mandate, the total number of H shares which may be repurchased by the Company shall not exceed 5% of the total number of H shares in issue (excluding treasury shares) as at the date of passing of the relevant resolution at the EGM. The Repurchase Mandate shall, from the date on which it was passed at the general meeting, remain in force until the earlier of: (1) the conclusion of the next general meeting of the Company following its passing at the general meeting; or (2) the date on which the Repurchase Mandate is revoked or varied by a relevant resolution passed by the shareholders at a general meeting. The Directors have no present intention to exercise the Repurchase Mandate to an extent which may result in any mandatory offer being made under the Takeovers Code, nor do they have any intention to exercise the Repurchase Mandate to the effect that it will result in the public float falling below the percentage as required under the Listing Rules or such other minimum percentage agreed by the Stock Exchange from time to time.

The Board is also of the view that the Company's current financial resources would enable it to implement the repurchase of H Shares while maintaining a sound financial position, and that such repurchase of H Shares would not have a material adverse effect on the Company's working capital requirements or gearing levels.

The proposed grant of the H Share Repurchase Mandate is subject to approval by the shareholders by way of a special resolution at the EGM. The Company will not repurchase any H shares prior to obtaining the Repurchase Mandate. A circular containing details of the proposed grant of the H Share Repurchase Mandate and the notice of the EGM will be despatched to the shareholders in due course in accordance with the requirements of the Listing Rules.

Shareholders and potential investors of the Company should note that any repurchase of H Shares by the Company shall be subject to the Company's actual needs and market conditions, and determined at the sole discretion of the Board and/or its authorised person(s). There is no assurance as to the timing, quantity or price of any repurchase of H Shares, or whether the Company will make any such repurchase. Accordingly, Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Beijing Shougang LanzaTech Technology Co., Ltd.
Executive Director and General Manager
Ms. Dong Yan

Hong Kong, November 9, 2026

As at the date of this announcement, the Board comprises: (i) Ms. Dong Yan and Mr. Lin Siyu as executive directors; (ii) Dr. Ma Lishen, Dr. Jennifer Holmgren, Dr. Wu Bin and Ms. Wang Yan as non-executive directors; and (iii) Dr. Hu Shanying, Dr. Feng Yingang, Dr. Chen Xin and Mr. Hoong Cheong Thard as independent non-executive directors.